Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 19/20 | 0.65 |
| ▸ | ERBB2 | P04626 | 14/20 | 0.65 |
| ▸ | GAK | O14976 | 1/20 | 0.59 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.57 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27736362 | 0.88 | EGFR (0.64) | EGFRERBB2GAKERBB3ERBB4 | |
| SCHEMBL19089647 | 0.86 | EGFR (0.63) | EGFRERBB2GAKERBB3ERBB4 | |
| SCHEMBL6979972 | 0.86 | LMNA (0.50) | EGFRERBB2GAK | |
| SCHEMBL22967644 | 0.86 | EGFR (0.62) | EGFRERBB2GAKERBB3ERBB4 | |
| SCHEMBL6961577 | 0.86 | EGFR (0.61) | EGFRERBB2GAKERBB3ERBB4 | |
| SCHEMBL6980764 | 0.85 | MRGPRX4 (0.54) | EGFRERBB2GAK | |
| SCHEMBL22793766 | 0.85 | PPARA (0.51) | EGFRERBB2GAK | |
| SCHEMBL14878664 | 0.84 | EGFR (0.79) | EGFRERBB2GAKERBB3ERBB4 | |
| SCHEMBL9975338 | 0.84 | ACP1 (0.55) | EGFRERBB2 | |
| SCHEMBL21340751 | 0.84 | EGFR (0.53) | EGFRERBB2GAK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11548900-B2 | Oxazino-quinazoline and oxazino-quinoline type compound, preparation method and uses thereof | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2023-01-10 | — | — | US | disclosed |
| EP-3760633-B1 | OXAZINO-QUINAZOLINE AND OXAZINO-QUINAZOLINE TYPE COMPOUND, PREPARATION METHOD THEREFOR, AND USES THEREOF | BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) | 2021-12-15 | — | — | EP | disclosed |
| US-20210040114-A1 | OXAZINO-QUINAZOLINE AND OXAZINO-QUINOLINE TYPE COMPOUND, PREPARATION METHOD AND USES THEREOF | ACCSALUS BIOSCIENCES LIMITED (VG) | 2021-02-11 | — | — | US | disclosed |
| EP-3760633-A1 | OXAZINO-QUINAZOLINE AND OXAZINO-QUINAZOLINE TYPE COMPOUND, PREPARATION METHOD THEREFOR, AND USES THEREOF | Beijing Scitech-MQ Pharmaceuticals Limited (CN) | 2021-01-06 | — | — | EP | disclosed |
| WO-2019170088-A1 | OXAZINO-QUINAZOLINE AND OXAZINO-QUINAZOLINE TYPE COMPOUND, PREPARATION METHOD THEREFOR, AND USES THEREOF | 北京赛特明强医药科技有限公司 | 2019-09-12 | — | — | WO | disclosed |
| US-10342796-B2 | Acrylanilide derivative, preparation method, and applications thereof in pharmacy | ANCUREALL PHARMACEUTICAL (SHANGHAI) CO., LTD. (CN) | 2019-07-09 | — | — | US | disclosed |
| US-20190015413-A1 | ACRYLANILIDE DERIVATIVE, PREPARATION METHOD, AND APPLICATIONS THEREOF IN PHARMACY | ANCUREALL PHARMACEUTICAL (SHANGHAI) CO., LTD. (CN) | 2019-01-17 | — | — | US | disclosed |
| WO-2017114500-A1 | ACRYLANILIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATIONS THEREOF IN PHARMACY | 恩瑞生物医药科技（上海）有限公司 | 2017-07-06 | — | — | WO | disclosed |
| US-8202879-B2 | Quinazoline derivatives having tyrosine kinase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2012-06-19 | — | — | US | disclosed |
| US-20090143414-A1 | Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity | SHIONOGI & CO., LTD. (JP) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10342796-B2 | Acrylanilide derivative, preparation method, and applications thereof in pharmacy | EGFR, ABL1, CSNK1A1 | EGFR 1/4885ERBB2 4/4885GAK 219/4885 |
| US-20190015413-A1 | ACRYLANILIDE DERIVATIVE, PREPARATION METHOD, AND APPLICATIONS THEREOF IN PHARMACY | EGFR, ABL1, CSNK1A1 | EGFR 1/4885ERBB2 4/4885GAK 219/4885 |
| US-20090143414-A1 | Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity | ERBB2, EGFR, ABL1 | EGFR 2/4885ERBB2 1/4885GAK 340/4885 |
| US-11548900-B2 | Oxazino-quinazoline and oxazino-quinoline type compound, preparation method and uses thereof | WNK1, WNK2, WNK3 | EGFR 3163/4885ERBB2 912/4885GAK 174/4885 |
| US-20210040114-A1 | OXAZINO-QUINAZOLINE AND OXAZINO-QUINOLINE TYPE COMPOUND, PREPARATION METHOD AND USES THEREOF | WNK1, WNK2, WNK3 | EGFR 3163/4885ERBB2 912/4885GAK 174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.